Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s Projects 50% Growth In U.S. OTC Business

This article was originally published in The Tan Sheet

Executive Summary

The Indian private labeler predicts annualized U.S. OTC sales of $200 million by March 2013. Dr. Reddy’s recently launched an equivalent of Allegra-D 24 Hour and plans to introduce generic Prevacid 24HR in its next fiscal year.

You may also be interested in...



Dr. Reddy’s Moves Quick On First Generic Allegra-D 12 Hour Extended Release

Generics of fexofenadine-only Allegra and fexofenadine/pseudoephedrine Allegra-D 24 Hour launched soon after the branded product’s switch in 2011, Dr. Reddy’s abbreviated NDA for a generic of Allegra-D 12 Hour Allergy & Congestion is the first approved by FDA.

Dr. Reddy’s Moves Quick On First Generic Allegra-D 12 Hour Extended Release

Generics of fexofenadine-only Allegra and fexofenadine/pseudoephedrine Allegra-D 24 Hour launched soon after the branded product’s switch in 2011, Dr. Reddy’s abbreviated NDA for a generic of Allegra-D 12 Hour Allergy & Congestion is the first approved by FDA.

Perrigo’s Mucinex Equivalent On The Cusp, But New Product Outlook Dims

The private labeler’s long-delayed guaifenesin launch now tentatively is set for March, CEO Joseph Papa says. But unclear timelines for other OTC launches caused Perrigo to lower its fiscal year consolidated new product sales outlook to $150 million from an initial projection of more than $190 million.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel